784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial
Bibliographic record
Abstract
Lower extremity peripheral arterial disease (PAD) is caused by atherosclerosis of leg arteries and may result in severe functional impairment. People with type 2 diabetes (T2D) are at higher risk of developing PAD than those without T2D. We present baseline data from STRIDE, a phase 3 trial investigating functional outcomes of semaglutide treatment in patients with PAD and T2D. STRIDE enrolled 792 patients with PAD (Fontaine IIa claudication) and T2D who were randomized to either 1 mg once-weekly subcutaneous semaglutide or placebo for 52 weeks. The primary outcome is change in maximum walking distance on a constant load treadmill. Baseline characteristics, comorbidities and medications were recorded. Median age was 68, 75.4% male, a median duration of T2D of 12 years, mean HbA1c 7.3% and LDL-C 2.0 mmol/L. CVD related history included: hypertension (87.9%), coronary disease (42.4%), coronary revascularization (31.4%), MI (18.7%), coronary artery stenosis >50% (27.5%), stroke (6.4%), transient ischemic attack (3.9%), chronic heart failure (13.6%), and chronic kidney disease (15.8%). More than a third were on SGLT2is. Baseline medications are shown in table 1. We highlight the high CVD burden and the baseline medications of patients in STRIDE, representing a study population with multiple comorbid risk factors and reasonably well controlled T2D. Disclosure N. Rasouli: Advisory Panel; Eli Lilly and Company, Novo Nordisk. Research Support; Novo Nordisk. A. Catarig: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. Y. Hansen: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. K. Houlind: Consultant; LeMaitre. C. Ramesh: None. B. Ludvik: Speaker's Bureau; Novo Nordisk. Research Support; Lilly Diabetes. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Bayer Inc. Speaker's Bureau; AstraZeneca. Research Support; Lilly Diabetes, Novo Nordisk, Boehringer-Ingelheim. Advisory Panel; Novo Nordisk, Lilly Diabetes. J. Nordanstig: Advisory Panel; AstraZeneca, Bayer Inc. Research Support; Artivion. H. Sourij: Advisory Panel; Amarin Corporation. Speaker's Bureau; Amgen Inc., Amarin Corporation, Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novartis AG. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Sanofi. Speaker's Bureau; Sanofi. Consultant; K:Businesscom. S. Verma: Other Relationship; Amarin Corporation, Amgen Inc., AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Novo Nordisk, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., S&L Solutions Event Management, Sanofi. M.P. Bonaca: Other Relationship; CPC Clinical Research.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".